Introduction {#Sec1}
============

Interleukin-25(IL-25), also known as IL-17E, is the most distinct member of the IL-17 cytokine family. Originally identified as homology to IL-17 family members (Fort et al. [@CR7]; Lee et al. [@CR13]), IL-25 was initially found to accumulate in polarized Th2 cells (Fort et al. [@CR7]). Related studies also demonstrated that other cell types from hematopoietic or non-hematopoietic compartments could produce IL-25 under certain circumstances, such as primary bone marrow-derived mast cells upon IgE cross-linking (Ikeda et al. [@CR11]), eosinophils and basophiles upon stem cell factor stimulation (Dolgachev et al. [@CR6]; Wang et al. [@CR23]), lung epithelial cells upon allergic response (Angkasekwinai et al. [@CR1]), and alveolar macrophages after particle inhalation (Kang et al. [@CR12]). The accumulation of IL-25 could also be seen in intestinal epithelial cells and brain capillary endothelial cells (Sonobe et al. [@CR21]; Zaph et al. [@CR26]). Many investigations confirmed the ability of different cell types to produce IL-25, while the mechanisms to control IL-25 production remain unclear.

IL-25 share the same receptor with IL-17B, named IL-17RB, IL-17BR, or Evi27, which was also identified based on sequence similarity to the IL-17 receptor. However, IL-25 has higher binding affinity to IL-17RB compared to that of IL-17B (Lee et al. [@CR13]; Shi et al. [@CR20]; Tian et al. [@CR22]). Further study showed that IL-17RA and IL-17RB are both required for activating signals in response to IL-25, although IL-25 did not bind to IL-17RA (Rickel et al. [@CR19]). Currently, the downstream targets of IL-25 signaling pathway still remain unclear.

As a distinct cytokine of the IL-17 family, IL-25 has the least structural homology with the prototypical IL-17 family member, IL-17A, which indicated why its biologic activities are distinct from other IL-17 family members. The cytokines of IL-17 family, not IL-25, induce the production of proinflammatory cytokines and play similar roles in the development of certain diseases. Alternatively, IL-25 has its unique abilities in regulating Th2 cell-type immune responses. It also plays a decisive role both in the induction of a protective response against parasites and in the initiation of innate and adaptive pro-allergic responses (Monteleone et al. [@CR16]). It is interesting that IL-25 was also involved in anti-tumor (Benatar et al. [@CR2], [@CR3]) and anti-inflammatory activities based on various studies of human and animal models (Mchenga et al. [@CR15]).

Until now, the recombinant human IL-25 (rhIL-25) is transiently produced using recombinant adenovirus or expressed in cell lines including human embryonic kidney (HEK) 293 cells or Sf9 insect cells on a small scale (Fort et al. [@CR7]; Hurst et al. [@CR9]). Commercial rhIL-25 is generated from an *Escherichia coli* expression system which may involve proper fold problem. In this study, using a eukaryotic expression system of *P. pastoris*, we established a more efficient and cost-effective method to produce functional rhIL-25 in large quantities. This will facilitate further study of its mechanisms in the pathogenesis of immune diseases, the structure--function relationship, and possible clinical applications.

Materials and methods {#Sec2}
=====================

Strains and reagents {#Sec3}
--------------------

*P. pastoris* strain X-33, expression vector pPICZαA, and antibiotic zeocin were products from Invitrogen (USA). Mouse anti-human IL-25 monoclonal antibody and *E. coli*-derived rhIL-25 were purchased from R&D (USA). Restriction enzymes were products of New England Biolabs (USA). Primers were synthesized by Sangon Biological Co., Ltd. (Shanghai, China). Other reagents were obtained from standard commercial sources and were of reagent grade.

Synthesis of human *IL-25* gene and construction of expression vector {#Sec4}
---------------------------------------------------------------------

To improve the production of recombinant hIL-25 in *P. pastoris*, we carried out a codon optimization of the *hIL-25* gene and constructed an artificial gene according to the specific codon usage of *P. pastori*s (codon usage database from <http://www.kazusa.or.jp/codon>). We designed a cloning approach based on synthetic overlapping primers and a PCR assembly strategy to construct a synthetic *hIL-25* cDNA fragment without the signal peptide sequence (Xiong et al. [@CR25]). The *hIL-25* cDNA (GenBank accession number BC069565) was used as template for optimization to generate a set of ten overlapping oligonucleotides (as showed in Table [1](#Tab1){ref-type="table"}), of which G+C content was adjusted to meet codon preference. A mixture of the oligonucleotides (10 ng each) was used in a first-round ten cycles of PCR procedure using *pfu* polymerase to generate most sections of the coding sequence. Then, the region for *Xho*I restriction site and Kex2 and Ste13 cleavage sites of α-factor signal sequence of *P. pastoris* were added to the 5′ terminal of the synthesized fragment in the second-round PCR using the most 5′ end primer N1 (see Table [1](#Tab1){ref-type="table"}). At the same time, *Not*I restriction site was linked to the 3′-terminal using the most 3′ end primer C1. The complete artificial DNA was first cloned into the *Xho*I--*Not*I frame of vector pBluescript SK and confirmed by automated DNA sequencing. Then, the certified fragment was directly cloned into pPICZαA, in-frame with the α-factor signal sequence under the control of the *AOX*1 promoter. The C-terminal stop codon to terminate translation is immediate after the last amino acid of hIL-25.Table 1Primers used for the synthesis of optimized *hIL-25* genePrimerOligonucleotide sequences (5′--3′)^a^OrientationF1ATACTCTCATTGGCCATCTTGTTGTCCATCTAAGGGTCAAGACACCTCTGAAGAATTGTTGSenseR2BTAGCTGGTTCTAAAGGTGGAACTGGAACAGTAGACCATCTCAACAATTCTTCAGAGGTGTAnti-senseF3CTCCACCTTTAGAACCAGCTAGACCAAACAGACATCCAGAATCTTGTAGAGCTTCTGAAGASenseR4DGTATCTCCAAGGAGAAATAGCTCTGGAGTTAAGTGGACCATCTTCAGAAGCTCTACAAGAAnti-senseF5ECTATTTCTCCTTGGAGATACGAATTGGATAGAGATTTGAACAGATTGCCACAAGATTTGTSenseR6FTGCAAAGAAACACAATGTGGACACAAACATCTAGCATGGTACAAATCTTGTGGCAATCTGAnti-senseF7GCCACATTGTGTTTCTTTGCAAACTGGTTCTCATATGGACCCAAGAGGTAACTCTGAATTGSenseR8HGACATGGTCTTCTGTAGAAGACAGTTTGGTTATGGTACAACAATTCAGAGTTACCTCTTGAnti-senseF9ICTTCTACAGAAGACCATGTCATGGTGAAAAGGGTACTCATAAGGGTTACTGTTTGGAAAGSenseR10JTCTAACACAAACACAAGCCAAAGAAACTCTGTACAATCTTCTTTCCAAACAGTAACCCTTAnti-senseN1TCT*CTCGAG*AAAAGAGAGGCTGAAGCTTACTCTCATTGGCCATCTTGSenseC1ATATTTTA*GCGGCCGC*TTAACCCATAACTCTTGGTCTAACACAAACACAAGCCAAnti-sense^a^Sequences added to introduce restriction endonuclease recognition sites (*Xho*I and *Not*I) are italicized

Transformation of *P. pastoris* and screening {#Sec5}
---------------------------------------------

Yeast transformation was performed on an electroporation system (Bio-Rad, USA) according to the manufacturer\'s instruction. The recombinant vector pPICZαA-*hIL-25* was linearized with *Sac*I and electroporated into competent *P. pastoris* strain X-33. The electroporated mixture was spread on YPDS plates (1 % yeast extract, 2 % peptone, 2 % glucose, 1 mol/l sorbitol, 2 % agar) containing 100 μg/ml, 500 μg/ml, 1 mg/ml, or 2 mg/ml zeocin, respectively, for growth selection. After 72 h of incubation at 30 °C, the positive colonies were certified for integration of *hIL-25* gene into the *Pichia* genome by PCR using the primers of 5′ *AOX*, 3′ *AOX*, and IL-25 gene-specific primers. The confirmed transformants were kept for further analysis.

Shake flask expression screening of rhIL-25 expression stain {#Sec6}
------------------------------------------------------------

The positive transformants were tested for their ability to secret rhIL-25 into the culture medium. Five milliliters of MGYH medium (1.34 % YNB, 1 % glycerol, 4 × 10^−5^ % biotin, 0.004 % histidine) of shake flask cultures from the *P. pastoris* clones (*hIL-25*/X-33 clones) was grown overnight at 30 °C in 25-ml baffled flasks (250 rpm) to an OD~600~ between 2 and 6. The cultures were centrifuged for 5 min at 3,000 *g.* The pellets were then transferred to 20 ml of MMH (1.34 % YNB, 4 × 10^−5^ % biotin, 0.5 % methanol, 0.004 % histidine) medium to culture at OD~600~ of 1.0 in 100-ml baffled flasks to induce expression at 30 °C. In each of the following 4 days, pure methanol was added to the culture to a final concentration of 1 % (*v*/*v*), while 200 μl of cell culture was collected and centrifuged at 12,000 *g* for 5 min at 4 °C. Supernatants were collected to monitor the expression and secretion of rhIL-25 by SDS-PAGE separation, followed by Coomassie blue stain.

Bench-scale fermentation and purification procedure {#Sec7}
---------------------------------------------------

Fermentations were performed in a 5-l working volume bioreactor (Bioflo 3000, New Brunswick Scientific, USA) according to Invitrogen instructions for *P. pastoris* fermentation. Two liters of basal salts medium (4.25 ml/l orthophosphoric acid, 9.4 mM MgSO~4~, 1 mM CaSO~2~, 16.4 mM K~2~SO~4~, 11.4 mM KOH, and 50 ml/l glycerol) was sterilized in the bioreactor. Ammonium was used as both a pH control reagent and a nitrogen source. PTM1 trace salts (2 ml/l; 24 mM CuSO~4,~ 0.53 mM NaI, 19.87 mM MnSO~4~, and 0.83 mM Na~2~MoO~4,~ 0.32 mM boric acid, 2.1 mM CoCl~2~, 0.15 mM ZnCl~2~, 0.23 M FeSO~4~, and 0.82 mM biotin) were added after sterilization. The certified rhIL-25 producing *P. pastoris* strain was grown as seed broth in 200 ml of BMGY (2 % peptone, 1 % yeast extract, 100 mm potassium phosphate, pH 6.0, 1.34 % yeast nitrogen base (without amino acid), 0.4 μg/ml biotin, 1 % glycerol) overnight till OD~260~ reached 4 and then inoculated into 2.0 L basal salts medium in a fermentor.

Throughout the fermentation process, temperature, dissolved oxygen (DO) concentration, and pH were monitored and maintained at set points of 30 °C, 30 % and 5.0, respectively. DO concentration was maintained above 30 % by enriching the inlet air with pure oxygen passing through a mass flow controller when needed. A glycerol-fed-batch phase was carried out in which biomass was bulked up to the desired cell density using 50 % glycerol feed containing 12 ml/l PTM1 trace salt. The exhaustion of glycerol was indicated by a spike in the DO, which happened 24--26 h after inoculation to the OD value at 600 nm reached around 100--120. After the growth phase on glycerol was finished, induction was carried out by feeding methanol (containing 12 ml/l PTM1) at a gradient feed rate into the fermentor.

The induction phase was maintained for 44 h, and then the culture medium was centrifuged at 8,000 *g* for 30 min at 4 °C. The supernatant was clarified by a bacterial filter (0.45 μm) and concentrated by ultrafiltration using a Pellicon cassette (Millipore, USA) with a molecular cutoff of 1,000 Da. The retention liquid was then run a buffer exchange against 50 mM Tris-Cl, 1 mM EDTA (pH 8.8), and loaded onto Q sepharose Fast Flow anion-exchange resin (GE healthcare, USA) equilibrated by the same buffer. The flow-through, which contained rhIL-25, was collected and further depurated through a gel filtration chromatography medium Sephacryl S-100 High Resolution (GE healthcare, USA) balanced with 20 mM PB (pH7.4). Fractions of purified rhIL-25 were lyophilized after the addition of trehalose to a final concentration of 15 %.

SDS-PAGE and western blot analysis {#Sec8}
----------------------------------

Protein samples were separated on 15 % SDS-PAGE gels and stained with sliver or Coomassie Blue R-250. To characterize the recombinant hIL-25, samples were also electroblotted onto PVDF membrane (Millipore,USA) using Mini Trans-Blot® Cell (Bio-Rad, USA) according to the manufacturer\'s instructions. The membrane was blocked with 5 % milk in TBST (10 M Tris--HCl, 150 mM NaCl, pH 8.0, and 0.1 % Tween 20) for 2 h at room temperature. The membrane was then incubated for 2 h at room temperature with mouse anti-hIL-25 monoclonal antibody (R&D,USA). After washing four times with TBST, the membrane was incubated for 1 h with peroxidase-conjugated goat anti-mouse IgG (R&D, USA). The membrane was washed three times with TBST, and the blot was visualized by chemiluminescence via the Pierce SuperSignal ECL detection kit (Pierce, Thermo Fisher, USA). N-terminal sequencing of rhIL-25 was performed by Shanghai Applied Protein Technology Co. Ltd.

IL-25 interaction assay {#Sec9}
-----------------------

The binding ability of recombinant rhIL-25 to its conjugate IL-17RB (also IL-17BR) was tested by pull-down assay. Purified rhIL-25 was incubated with IL-17BR-Fc chimera (R&D, USA) in fresh phosphate-buffered saline (PBS, pH 7.4) for 1 h at room temperature. The IL-17BR-Fc was pulled down by its Fc-tag using rProteinA Resin (GE Healthcare, USA). The beads were washed with PBS three times and then eluted with 0.1 M glycine-HCl (pH3.0). A donkey anti-goat IgG (Santa Cruz, USA) was also used instead of IL-17BR-Fc as a negative control.

In vitro biological activity assay {#Sec10}
----------------------------------

Biological activity was determined by adding rhIL-25 preparations to HEK293 cells or human lung fibroblast cell line HFL-I cells (Cat. GNHu43 and GNHu 5, respectively; Shanghai Cell Collection, SIBS, Shanghai, China) to assay G-CSF mRNA and protein expression level changes. The HEK293 cells were cultured at 2 × 10^5^ cells per well in six-well plates (Corning, USA) in 2 ml DMEM medium (Gibco, USA) containing 10 % new-born calf serum (NCS) at 37 °C, 5 % CO~2~, while the HFL-I cells were cultured at 1 × 10^5^ cells per well in MEMα medium containing 10 % heat-inactivated fetal bovine serum (FBS). Then, the cells were starved of serum for 24 h. Purified rhIL-25 was diluted and added into a six-well plate (2 ml/well) in triplicate to reach concentrations of 50, 100, 200, and 400 ng/ml. After 24 h of incubation, the cells were lysed for RNA extraction using TRIzol reagent and operated according to manufacturer\'s instruction (Invitrogen). First-strand cDNA synthesis was performed using RevertAid First Strand cDNA synthesis kit (Invitrogen). The product of first-strand cDNA synthesis was used directly for real-time PCR assay. The primers used for G-CSF amplification were 5′-CAGTTACAATGTGACAGTGGAGGG-3′ and 5′-TTTGACTCCCGAACATCACCGAC-3′, respectively. Commercially available recombinant hIL-25 derived from *E. coli* (R&D, USA) was also used as control. The mRNA level of GAPDH was used as normalization control.

G-CSF production in cell culture supernatant was also assayed using a human G-CSF quantikine ELISA kit (R&D). The cell culture and rhIL-25 treatment is the same as that for real-time PCR. After 24 h treatment with rhIL-25, the culture supernatant was collected for ELISA assay according the manufacturer\'s manual.

Hoechst staining and flow cytometric assay of apoptosis {#Sec11}
-------------------------------------------------------

Two breast cancer cell lines, HBL-100 (Cat. GNHu10, Shanghai Cell Collection, SIBS) and MDA-MB-231 (No. HTB-26, ATCC, USA), were seeded at a density of 1 × 10^5^ cells per well in 0.5 ml DMEM medium containing 10 % NCS in a 24-well plate (Corning, USA) and cultured to 80 % saturation at 37 °C, 5 % CO~2~. After 12 h of serum starvation, cells were treated with rhIL-25 for 4 or 24 h at 37 °C, 5 % CO~2~. At indicated time, cells were washed twice with PBS, then Hoechst 33342 solution (Invitrogen) was added at 1 μg/ml, and incubated for 30 min at room temperature. Images were taken with a fluorescene microscope (IX71, Olympus, Japan).

Apoptotic cells were measured by annexin V-FITC/propidium iodide (PI) staining and flow cytometry. Briefly, HBL-100 and MDA-MB-231 cells were seeded at a density of 4 × 10^5^ cells per well in a six-well plate and cultured to 80 % saturation at 37 °C, 5 % CO~2~. After 12 h of serum starvation, cells were treated with gradient concentration of rhIL-25 for 8 h at 37 °C, 5 % CO~2~. After that, cells were harvested using citric acid, washed twice with cold PBS, and then resuspened in 500 μl binding buffer. Afterward, 5 μl annexin V-FITC and 5 μl PI (BD, USA) were added and incubated with cells for 15 min in the dark at room temperature and then analyzed on a flow cytometer (Epics Altra system, Beckmen-Coulter, USA; analysis software is EXPO32 V1.2 Analysis). Early apoptotic (lower right quadrant) and late apoptotic (upper right quadrant) cells were identified and expressed as percentage of cells.

GenBank accession numbers {#Sec12}
-------------------------

The accession number of wild-type IL-25 is BC069565; the accession number of codon-optimized IL-25 is KF360054.

Results {#Sec13}
=======

Construction of the recombinant expression vector {#Sec14}
-------------------------------------------------

The full-length of *hIL-25* cDNA was 534 bp, encoding a polypeptide of 177 amino acid residues with a putative signal sequence and pre-peptide of 32 amino acid residues. The 438-bp fragment coding for mature IL-25 proceeded for codon optimization based on *P. pastoris* preference for efficiency of rhIL-25 production. The sequence alignment result showed that the codon-optimized *IL-25* shares 72 % identity with the wild-type *IL-25* after averaging the distribution of G+C content and eliminating the potential hairpin structure. The substitute of nucleotides does not alter their coding amino acid sequences. DNA sequencing of the recombinant vector confirmed the accuracy of the reading frame of *IL-25*. The synthesized DNA was directly inserted into the open reading frame of α-factor signal sequence of the *P. pastoris* expression vector pPICZαA under the regulation of *AOX*1 promoter.

Transformation and screening of transformants at shaking flask level {#Sec15}
--------------------------------------------------------------------

The resulting vector, pPICZαA-r*hIL-25*, was transformed into *P. pastoris* by electroporation and plated on YPDS medium containing increasing concentrations of zeocin for the rapid screening of multi-copy transformants. The number of transformants decreased with the increase of antibiotic concentration after 3 days of incubation. Colony PCR screening of the positive recombinant was performed to confirm the integration of recombinant vector into the *Pichia* genome.

Then, positive colonies were cultured and induced to express the recombinant proteins according to the manufacturer\'s instruction. Transformants from YPDS plates in the presence of different concentrations of zeocin were selected for expression screening. SDS-PAGE and western blot analysis showed that rhIL-25 was successfully expressed in the culture medium of *P. pastoris* X-33 transformants. Secreted rhIL-25 from wild-type *hIL-25* transformants could be detected in silver-stained gel, while it could be clearly identified with Coomassie blue staining in codon-optimized transformants (shown in Fig. [1](#Fig1){ref-type="fig"}). The product demonstrated as a 17- and a 34-kDa band; both bands were identified by western blot using a mouse anti-hIL-25 monoclonal antibody. The 34-kDa band was considered to be a homodimer form of the 17-kDa hIL-25. SDS-PAGE also showed a progressive accumulation of the rhIL-25, starting at 24 h post-induction, and reached the peak at 96 h. Prolonged induction could not increase the amount of total rhIL-25 in the culture supernatant.Fig. 1Analysis of total proteins in culture medium of *P. pastoris* expressing rhIL-25. Supernatants were collected at the indicated time after induction by methanol. The samples were separated on 15 % SDS-PAGE and stained with silver (**a**) or Coomassie brilliant blue (**c**, **d**). **a** Shake flask culture medium of *P. pastoris* strain X-33 transformed by wild *hIL25*. **b** Western blot analysis. **c**, **d** Fermentation culture supernatants of X-33 transformed by codon-optimized *hIL25*. **c** Non-reduction, loading buffer without β-mercaptoethanol. **d** Reduction, loading buffer with β-mercaptoethanol

Large-scale expression and purification of rhIL-25 {#Sec16}
--------------------------------------------------

One of the transformants with highest expression was grown on a 5-l bioreactor and induced with methanol for 48 h. Culture medium was collected and centrifuged to generate supernatant every 4 h. The recombinant protein expression started 16 h after methanol induction and reached the peak at 44 h (shown in Fig. [1](#Fig1){ref-type="fig"}). At the end of fermentation, the wet weight of yeast reached 260 g per liter of broth volume, while the volume of supernatant increased to 2.6 L. The rhIL-25 in culture supernatant was estimated to be 100 mg/l based on SDS-PAGE results. The culture supernatant was collected and concentrated using membrane ultrafiltration. Subsequently, rhIL-25 was allowed to pass through the Q sepharose Fast Flow column, while most of the contaminants were absorbed (Shown in Fig. [2](#Fig2){ref-type="fig"}). The rhIL-25 was further polished through high-resolution gel filtration to remove trace impurities. Finally, we got 39.6 mg purified rhIL-25 per liter of culture supernatant in monomer form.Fig. 2Purification of rhIL-25 protein. **a** The fermentation supernatant was concentrated by ultrafiltration and then the buffer exchanged against 50 mM Tris--HCl and 1 mM EDTA, loaded onto Q sepharose Fast Flow resin, and eluted using NaCl gradient from 0 to 1 M. The rhIL-25 protein was flowing through the Q Sepharose FF, while the containments were bound by the column. **b** The fractions were separated on 15 % SDS-PAGE. Lane *M* molecular weight marker. Lane *1* fermentation supernatant at 44 h after methanol induction. Lane *2* after buffer exchange. Lane *3* flow-through of Q FF. Lane *4* wash-off using balance buffer. Lane *5*--*9* eluate from Q Sepharose FF

N-terminal sequencing result indicated that the five amino acid residues at the N-terminal of the rhIL-25 were YSHWP, which matched with that of the deduced mature IL-25.

Functional characterization and bioactivity assay of rhIL-25 {#Sec17}
------------------------------------------------------------

The functionality of rhIL-25 was evaluated by testing its capacity to bind IL-17BR using a pull-down assay. As shown in Fig. [3](#Fig3){ref-type="fig"}, we detected the specific interaction of the purified recombinant rhIL-25 with IL-17BR-Fc chimera. The rProteinA affinity gel was also used alone in this assay for it non-specifically binds to rhIL-25. The biological activity of rhIL-25 was detected by its ability to directly stimulate G-CSF production from two cell lines in vitro. As shown in Fig. [4](#Fig4){ref-type="fig"}, rhIL-25 stimulated G-CSF mRNA expression in both HEK293 and HFL-1 cells, with higher expression in HFL-1 cell. G-CSF protein production from HFL-1 cells was confirmed by ELISA. The activity of the purified rhIL-25 was comparable with the commercially available recombinant hIL-25.Fig. 3IL-17BR binding assay. Purified rhIL-25 was evaluated by its capacity to interact with IL-17BR. Recombinant hIL-25 was incubated with IL-17BR-Fc chimera and then pulled down with rProtein A resin which specifically binds the Fc-tag on IL-17BR-Fc chimera. Donkey anti-goat IgG was used as a negative control for non-specific binding. Bound proteins were analyzed by SDS-PAGE and Coomassie staining. Lanes represent flow-through (*1*), wash (*2*), and elution fractions (*3*) from the resin using **a** rhIL-25 only, **b** rhIL-25 incubated with IL-17BR-Fc chimera, and **c** rhIL-25 incubated with donkey anti-goat IgGFig. 4IL-25 induces G-CSF production. **a**, **b** IL-25 stimulates G-CSF mRNA expression in HFL-1 and HEK293 cells. The cells were treated with IL-25 and the mRNA expression level of G-CSF was examined by real-time RT-PCR. GAPDH mRNA levels were used as normalization controls. The data are presented as the fold increase after IL-25 induction compared with medium only (no IL-25 treatment) cell. **c** IL-25 induces the production of G-CSF protein, HFL-1 cells were treated with IL-25 in increased concentration for 24 h, and G-CSF levels in the culture medium were measured by ELISA

Recombinant hIL-25 induces apoptosis in breast cancer cells by annexin V-FITC/PI staining assay {#Sec18}
-----------------------------------------------------------------------------------------------

To investigate whether apoptosis occurs in rhIL-25-treated breast cancer cells, we performed a Hoechst33342 staining assay to detect apoptosis-induced chromosome fragmentation. Hoechst33342 staining was used to visualize the nuclear morphology following rhIL-25 treatment (shown in Fig. [5](#Fig5){ref-type="fig"}). Fluorescent signals were detected in nucleic regions of cells after 4 h of treatment with 50 ng/ml rhIL-25, and more obviously, morphologic changes of apoptosis such as condensed chromatin and shrunken nucleus were detected after 24 h of treatment.Fig. 5Fluorescence photomicrographs of two breast cancer cells with Hoechst 33242 staining after rhIL-25 treatment. **a**--**c** HBL-100 cells. **d**--**f**, MDA-MB-231 cells. **a**, **d** Untreated with rhIL-25. **b**, **e**, At 4 h after treatment with 50 ng/ml rhIL-25. **c**, **f** At 24 h after treatment with 50 ng/ml rhIL-25. ×400 magnification

To confirm the various stages of apoptosis or necrosis, MDA-MB-231 and HBL-100 cells were treated with the indicated concentrations of rhIL-25 for 8 h, followed with annexin V-FITC/PI staining and FACS analysis. Figure [6](#Fig6){ref-type="fig"} shows a dot--plot display produced from annexin V-FITC/PI with flow cytometry. After the administration of rhIL-25 for 8 h, apoptosis was induced in both cells in a dose-dependent manner.Fig. 6Cell apoptosis was induced with rhIL-25. After 8 h of treatment of rhIL-25 with indicated dosages, HBL-100 and MDA-MB-231 cells were harvested and stained with annexin V-fluorescein and PI. Percentage of annexin-V/PI stained cells was determined by flow cytometry

Discussion {#Sec19}
==========

The aim of the current work was to produce a large amount of soluble and bioactive rhIL-25 suitable for biological studies with less cost and no denaturing agents or refolding steps present in the *E. coli* expression system. Human IL-25 has been produced transiently in human 293 cells using recombinant adenovirus or Sf9 insect cells (Fort et al. [@CR7]; Hurst et al. [@CR9]), while the productivity of the recombinant protein was unknown. It was also produced as inclusion bodies in *E. coli*, which need denaturing and refolding steps (unpublished data in this laboratory).

Yeasts, particularly the methylotrophic yeast *P. pastoris*, have numerous advantages as a host system for the production of recombinant heterologous proteins. They are much easier to perform and cheaper in cost compared with that of bacterial expression systems. At the same time, *P. pastoris*, as a eukaryote, thereby provides the potential for producing soluble recombinant proteins with correct folding and post-translational modifications (Cregg et al. [@CR4]; Damasceno et al. [@CR5]).

To obtain the high-quality and extracellular expression of rhIL-25, we chose pPICZαA as the expression vector and *P. pastoris* X-33 as the host strain. Many proteins produced in *P. pastoris* are similar to those produced in mammalian cells based on synthesis, structure, and bioactivity. The expression vector pPICZαA has an α-factor secretion signal sequence, which has been used with great success. However, although the rhIL-25 was presently secreted in *P. pastoris*, the low secretion level using a wild-type gene restricted its yield, as shown in Fig. [1a, b](#Fig1){ref-type="fig"}; rhIL-25 can hardly be discriminated using silver staining. There are many factors that markedly influence the expression of foreign genes, including *P. pastoris* codon bias, base content of foreign genes, transcriptional and translational blocks, and secondary structure of mRNA (Cregg et al. [@CR4]; Woo et al. [@CR24]). To increase the secretion expression level, we optimized the gene of interest by means of substituting rare codons with *P. pichia* preferable triplets. At the same time, we balanced the G+C content, removed the A/T or G/C repeats, and avoided the formation of hairpin or special secondary structure of *hIL-25* mRNA(Li et al. [@CR14]). The productivity of rhIL-25 was much higher using codon optimized *rhIL-25*.

The function of rhIL-25 was verified by its binding capability with IL-17RB. The biological activity of rhIL-25 was confirmed by its ability to induce G-CSF production in pulmonary fibroblasts HFL-1 and renal epithelium cell HEK293, which is consistent with published results (Pan et al. [@CR18]). We also tried some breast cancer cell lines to detect whether they can produce G-CSF after rhIL-25 treatment. We found that more dominantly rhIL-25 can induce the death rate of breast cell. Apoptosis-induced chromosome fragmentation was detected using Hoechst33342 staining. Annexin V-FITC/PI staining assay indicated that rhIL-25 induced apoptosis in breast cancer cell MDA-MB-231 and HBL-100, which was in agreement with Furuta\'s report that IL-25 causes apoptosis of some breast cancer cells (Furuta et al. [@CR8]).

As observed by non-reduced and reduced SDS-PAGE, The rhIL-25 produced by *P. pastoris* was mainly homodimers, which is in agreement with the finding that IL-17s adopt a cystine knot fold (Hymowitz et al. [@CR10]). IL-17A had also been expressed in *P. pastoris* as both monomer and homodimer forms (Murphy et al. [@CR17]). IL-25 has 11 cysteines in total, more than that of IL-17A and other members in IL-17 family, which indicate its unique character. The exact disulfide bonds within polypeptide or between peptide chains need further study. In this study, although the homodimer form of rhIL-25 was shown in culture medium, the monomer form was the unique form after purification. The method of purification also indicated rhIL-25 having a distinctive structure. The bond in the homodimer is probably a weak disulfide bonds. To learn the distinct biological activity of this cytokine, further work is needed to assess the manner of dimerizing and the importance of inter-peptide disulfide bonds forming.

In conclusion, we have described a highly efficient way of producing large quantities of functional rhIL-25 using a *P. pastoris* expression system. This system may facilitate further studies of its structure--function relationship in the near future.
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